慢性乙型肝炎患者T淋巴细胞亚群与自然杀伤细胞活性分析

Investigation of T lymphocyte subsets and activity of natural killer cells in patients with chronic hepatitis B

目的分析慢性乙型肝炎患者外周血T淋巴细胞亚群与自然杀伤细胞(NK)的活性变化。方法应用流式细胞技术分别检测35名健康人(A组)、31例乙型肝炎病毒携带(B组)、32例慢性乙型肝炎患者(C组)、30例急性乙型肝炎患者(D组),外周血T淋巴细胞CD4+、CD8+以及NK细胞,并分析各组间免疫细胞表达差异性。结果 C、D组CD4+T淋巴细胞平均值为(32.45±10.45)%、(29.54±11.55)%较A、B组的(38.05±10.15)%、(37.17±11.22)%,明显降低,而CD8+T淋巴细胞平均值为(36.15±11.56)%、(38.45±10.35)%,较A组的(30.14±11.25)(%),明显升高(P<0.01);NK细胞则表现为C、D组平均值为(15.23±6.38)%、(12.07±5.95)%,较A、B组的(22.05±7.15)%、(20.32±7.67)%,明显降低(P<0.05),以D组降低最为明显,A、B组差异无统计学意义。结论慢性乙型肝炎和急性乙型肝炎患者外周血CD4+T淋巴细胞、NK细胞百分比降低,CD8+T淋巴细胞升高;通过T淋巴细胞和NK细胞百分比检测可监测慢性乙型肝炎患者的免疫状态,为临床治疗时机的选择提供免疫学依据。

OBJECTIVE To investigate the counts of natural killer（NK） cells and peripheral blood T lymphocyte subsets in patients with chronic hepatitis B.METHODS The CD4＋T cells,CD8＋ T cells,and NK cells in penripheral blood of 35 health persons（group A）,32 patients with hepatitis B virus（group B）,32 patients with chronic hepatitis B（group C） and 30 patients with acute hepatitis B（group D） were detected by using flow cytometry.RESULTS CD4＋ T lymphocytes and NK cells of group C（32.45±10.45）%and group D（29.54±11.55）% were decreased significantly as compared with group A（38.05±10.15）% and group B（37.17±11.22）%,while CD8＋ T lymphocytes of group C（36.15±11.56）% and group D（38.45±10.35）% was significantly increased as compared with group A（30.14±11.25）（P0.01）;the NK cells of group C（15.23±6.38）% and group D（12.07±5.95）% were significantly decreased as compared with the group A（22.05±7.15）% and group B（20.32±7.67）%,（P0.05）,group D decreased most significantly,the difference between group A and group B was not statistically significant.CONCLUSION The percentage of CD4＋ T lymphocyte cells and NK cells in the peripheral blood of the patients with chronic or acute hepatitis B is decreased,while the percentage of CD8＋ T lymphocyte cells is increased;through the detection of the percentage of T lymphocyte and NK cell we can monitor the immune status of the patients with chronic hepatitis B and get the reference of immunology for the clinical treatment.